Company intelligence / Profile preview
Fuzionaire Theranostics
The Woodlands, Texas, United Statesfuzionairetx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Fuzionaire Theranostics has presented initial preclinical data for its GRPR-targeting prostate cancer program. The company’s pipeline includes discovery-stage programs in lung cancer and PSMA/GRPR-positive prostate cancer. No active clinical trials are currently listed on ClinicalTrials.gov as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Radiopharmaceuticals (including PET diagnostics and radioligand therapies)peptide-based theranostics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaborations with academic institutions such as McGill University; seeking new partners to expand use of HetSiFA technology.
Beyond the preview
Go deeper on Fuzionaire Theranostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fuzionaire Theranostics.